Delivery Order SPE2DB20D2104-SPE2DB25FMYLA
- Not listed
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with fulfillment performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used primarily in the treatment of systemic lupus...
- The Defense Logistics Agency awarded a $9,248.01 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 7, 2025, with an ultimate completion date of August 28, 2025. Benlysta (belimumab) is a biologic immunosuppressant used primarily to treat systemic lupus erythematosus and other autoimmune conditions. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 11, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody biologic therapy indicated for treating systemic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on August 5, 2025, with completion targeted for August 26, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement utilizing the company's existing Indefinite Delivery Contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, supporting federal...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector pharmaceutical products with a ceiling value of $6,165.34 under a firm fixed-price contract. This non-set-aside delivery order, issued on August 1, 2025, is scheduled for ultimate completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injector on August 19, 2025, with completion targeted for September 10, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMYLADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 20, 2025, with completion scheduled for September 11, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used to treat systemic lupus erythematosus and other autoimmune conditions, reflecting the broad pharmaceutical portfolio that AmerisourceBergen supplies to federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of brand-name and generic medications, specialty drugs, vaccines, and medical supplies to support military healthcare programs and other federal customers including the Defense Health Agency and U.S. Coast Guard. The company's consistent performance on competitively awarded delivery orders demonstrates its capability to fulfill critical pharmaceutical procurement requirements across multiple therapeutic domains for the Department of Defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.2k | 8/20/25 |